This study aims to help researchers better understand the efficacy and safety of MC2-25 cream in patients with kidney disease-associated pruritus (CKD-aP)
CHRONIC KIDNEY DISEASE & PRURITUS
Key Study Information:
Chronic Kidney Disease and Pruritus
Trial Site Locations:
The Royal London Hospital, Hull University Teaching Hospital, Newcastle Hospitals NHS Foundation Trust, Nottingham University Teaching Hospital, Churchill Hospital, Oxford University
To evaluate the efficacy and safety of MC2-25 Cream and MC2-25 vehicle in subjects with chronic kidney disease-associated pruritus (CKD aP)
22 Patients: Non-Dialysis CKD stage 3
22 Patients: Non-dialysis CKD stage 4/5
Total: 44 Patients
- Details of practice revenue available on request.
Speak to our study support specialist for more information on this study.
10 minutes to participate in this study
Practice - Select a study
Your practice can choose a study via our website or dedicated web application.
Practice - Review & Approve Eligible Patients
uMed searches are compatible with EMIS or SystmOne. The results of this search are available to your practice in our web application for sign-off.
uMed - Patient Contact
We provide a dedicated study support line for all patient enquiries to minimise incoming calls to your practice.
For most studies, between 10-30% of patients engage with our outreach.
Patient - Consents to Join Study
Once the study concludes, we will share results and patient feedback with you so that you can see the impact of your participation. Any revenue generated from commercial studies is shared with your practice.
Register your interest in this study
Fill in the below form and a member of our team will be in touch to discuss next steps to participate in this study.